JP2022534118A5 - - Google Patents
Info
- Publication number
- JP2022534118A5 JP2022534118A5 JP2021570824A JP2021570824A JP2022534118A5 JP 2022534118 A5 JP2022534118 A5 JP 2022534118A5 JP 2021570824 A JP2021570824 A JP 2021570824A JP 2021570824 A JP2021570824 A JP 2021570824A JP 2022534118 A5 JP2022534118 A5 JP 2022534118A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- fgfr3
- infigratinib
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855277P | 2019-05-31 | 2019-05-31 | |
| US62/855,277 | 2019-05-31 | ||
| US201962906194P | 2019-09-26 | 2019-09-26 | |
| US62/906,194 | 2019-09-26 | ||
| PCT/US2020/035140 WO2020243442A1 (en) | 2019-05-31 | 2020-05-29 | Methods of treating urinary system cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534118A JP2022534118A (ja) | 2022-07-27 |
| JP2022534118A5 true JP2022534118A5 (https=) | 2023-05-19 |
Family
ID=73553913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570824A Pending JP2022534118A (ja) | 2019-05-31 | 2020-05-29 | 泌尿器系がんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220233537A1 (https=) |
| EP (1) | EP3976833A4 (https=) |
| JP (1) | JP2022534118A (https=) |
| KR (1) | KR20220088830A (https=) |
| CN (1) | CN114207151A (https=) |
| AU (1) | AU2020282816A1 (https=) |
| CA (1) | CA3141871A1 (https=) |
| IL (1) | IL288408A (https=) |
| MX (1) | MX2021014524A (https=) |
| PH (1) | PH12021552973A1 (https=) |
| SG (1) | SG11202112932QA (https=) |
| WO (1) | WO2020243442A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023007284A (es) * | 2020-12-18 | 2023-07-03 | Qed Therapeutics Inc | Metodos para el tratamiento de la acondroplasia. |
| TW202423445A (zh) * | 2022-11-01 | 2024-06-16 | 美商Ｑｅｄ醫藥股份有限公司 | 英菲格拉替尼在治療胃癌和腺癌中的用途 |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
| CN117558346B (zh) * | 2023-09-01 | 2024-12-03 | 上海仁东医学检验所有限公司 | Utuc分子分型及预后预测模型构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080080525A (ko) * | 2005-12-08 | 2008-09-04 | 노파르티스 아게 | 유전자 전사에 대한 ｆｇｆｒ３의 억제제의 효과 |
| CA3150658A1 (en) * | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| TWI541022B (zh) * | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| KR102470456B1 (ko) * | 2014-09-26 | 2022-11-23 | 얀센 파마슈티카 엔.브이. | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| TWI798199B (zh) * | 2017-02-06 | 2023-04-11 | 比利時商健生藥品公司 | 癌症治療 |
| CN111868260B (zh) * | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
-
2020
- 2020-05-29 AU AU2020282816A patent/AU2020282816A1/en not_active Abandoned
- 2020-05-29 US US17/613,652 patent/US20220233537A1/en not_active Abandoned
- 2020-05-29 KR KR1020217043300A patent/KR20220088830A/ko active Pending
- 2020-05-29 EP EP20815357.7A patent/EP3976833A4/en active Pending
- 2020-05-29 CA CA3141871A patent/CA3141871A1/en active Pending
- 2020-05-29 PH PH1/2021/552973A patent/PH12021552973A1/en unknown
- 2020-05-29 CN CN202080053765.5A patent/CN114207151A/zh active Pending
- 2020-05-29 SG SG11202112932QA patent/SG11202112932QA/en unknown
- 2020-05-29 MX MX2021014524A patent/MX2021014524A/es unknown
- 2020-05-29 WO PCT/US2020/035140 patent/WO2020243442A1/en not_active Ceased
- 2020-05-29 JP JP2021570824A patent/JP2022534118A/ja active Pending
-
2021
- 2021-11-25 IL IL288408A patent/IL288408A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534118A5 (https=) | ||
| Spitler | A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. | |
| KR20240056564A (ko) | T 세포 림프종을 치료하기 위한 약물을 제조하는 데 있어서 ezh2 억제제의 용도 | |
| JP5952890B2 (ja) | 膵臓癌を治療するための医薬製剤 | |
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| JP6462147B2 (ja) | Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用 | |
| JP5757544B2 (ja) | 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法 | |
| WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
| JP2023513704A5 (https=) | ||
| AU2017315357A1 (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| CN111184863B (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 | |
| CN117919234A (zh) | 一种萘酰胺化合物治疗耐药性肿瘤的用途 | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| BR112019015023A2 (pt) | Intensificadores de canibalismo celular para uso para sensibilizar tumores para terapia por radiação | |
| TW202110454A (zh) | Cdk4/6抑制劑與vegfr抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN109303781A (zh) | 川穹嗪在制备治疗子宫内膜异位症的药物中的应用 | |
| ES2554332T3 (es) | Utilización de la bencidamina en el tratamiento de las enfermedades dependientes de p40 | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| CN109963847A (zh) | 治疗实体瘤的方法 | |
| CN111728960B (zh) | 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用 | |
| CN111388665B (zh) | 一种治疗肿瘤的复合物及其制剂和用途 | |
| CN110339195A (zh) | 用于治疗胆管癌的喹啉衍生物 | |
| CN112826820B (zh) | Nlrp3抑制剂及其应用 | |
| CN118354772A (zh) | 治疗头颈癌的方法 | |
| JP7098054B2 (ja) | ２，３，５－置換されたチオフェン化合物の放射線治療増進用途 |